** Shares of drugmaker Krystal Biotech KRYS.O fall 9.8% to $146.4
** KRYS posts Q1 revenue of $88.2 million, missing analysts' average estimate of $96.24 million, according to data compiled by LSEG
** Co reports Q1 adj. profit of $1.20/share vs analysts' estimate of $1.37/share
** Krystal Biotech has one approved drug on the market, Vyjuvek, a gene therapy used to treat dystrophic epidermolysis bullosa (DEB), a rare genetic skin condition
** Patients with the condition suffer from open wounds, causing skin infections, and are at an increased risk of vision loss, scarring and skin cancer
** As of last close, KRYS stock up 3.6% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。